1. Introduction {#sec1-molecules-20-17469}
===============

*Staphylococcus aureus* (*S. aureus*) is a common pathogen causing serious hospital infections, community acquired infections and is also the pathogen with the highest drug resistant incidence. There are still no specific and selective antibacterial agents to kill MRSA (Methicillin-resistant *S. aureus*), which leads to a high death rate of patients \[[@B1-molecules-20-17469]\]. Resistance to antibacterial drugs has been relentlessly increasing over the past two decades, along with a noticeable decrease in the development of new drugs for infections \[[@B2-molecules-20-17469]\]. Few candidate drugs that offer benefits over existing drugs are available, and few drugs that will treat infections due to the so-called "ESKAPE" pathogens (*Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Enterobacter* spp.) are being developed \[[@B3-molecules-20-17469]\]. The need for newer, more effective treatment options for multidrug-resistant (MDR) pathogens induced the Infectious Diseases Society of America (IDSA) to launch the 10 × 20 initiative against a range of resistant "ESKAPE" pathogens including MRSA and to develop 10 new effective antimicrobial drugs to treat the infections caused by these pathogens by 2020 \[[@B4-molecules-20-17469]\]. Therefore, it is evident and urgent to seek a new defending strategy against MRSA now.

Bisoumarin and dihydropyran derivatives are widely available in nature. These derivatives exhibit various biological activities, such as anticoagulant, insecticidal, antihelminthic, hypnotic, and antifungal activities, phytoalexin production, and HIV protease inhibition \[[@B5-molecules-20-17469],[@B6-molecules-20-17469],[@B7-molecules-20-17469],[@B8-molecules-20-17469]\]. Moreover, the two kinds of compounds are gaining increasing interest because of their versatile activities through chemical modifications (different substituents on the aromatic ring) \[[@B9-molecules-20-17469]\]. For biscoumarins, the minimum active harmacophore reportedly consists of a coumarin dimer containing an aryl substituent on the central linker methylene. The addition of 4-hydroxy substituents to coumarin rings improved the potency of the compounds \[[@B10-molecules-20-17469]\]. Recognizing the considerable importance of the compounds, the researchers focused on the synthesis of bisoumarin and dihydropyran derivatives \[[@B11-molecules-20-17469]\].

To identify more active compounds, we prepared a series of biscoumarin and dihydropyran derivatives ([Figure 1](#molecules-20-17469-f001){ref-type="fig"}) and then evaluated their antibacterial activities. Finally, we calculated the total HB energies of compounds **1**--**4** by density functional theory (DFT) method to elucidate a possible relationship between such hydrogen-bonded structures and their antibacterial activities.

###### 

Chemical structures of compounds **1**--**13**.
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2. Results and Discussion {#sec2-molecules-20-17469}
=========================

2.1. Molecular Structure {#sec2dot1-molecules-20-17469}
------------------------

The crystal structures of compounds **4**, **5**, **8** and **12** are given in [Figure 2](#molecules-20-17469-f002){ref-type="fig"}. In the crystal structure of compound **4**, two crystallographically independent molecules are present in the asymmetric unit. The whole molecule is disordered over two orientations with refined site occupancies of 1:1, and two 4-hydroxycoumarin moieties are linked through a methylene bridge on which one hydrogen atom has been replaced with a 3-fluoro-4-chlorophenyl group. However, the two components differ with respect to the reversed twist directions of the 3-fluoro-4-chlorophenyl residue. In the compound, two classical intramolecular hydrogen bonds were found; each links a coumarin hydroxyl and carbonyl group \[*d*(O~3~--O~4~) = 2.598 Å, *d*(O~1~--O~6~) = 2.676 Å\].

###### 

Crystal structure of compounds **4**, **5**, **8** and **12**.

![](molecules-20-17469-g002a)

![](molecules-20-17469-g002b)

In compounds **5**, **8** and **12**, the new formed pyran ring is essentially planar because the maximum deviation of the atoms in the skeleton from the C~7~-O~3~-C~8~ plane is only 0.2533 Å in compound **5**, the corresponding value is 0.2006 Å and 0.6686 Å in compounds **8** and **12** respectively. The adjacent coumarin ring, naphthalene ring and ketone ring is also basically parallel to the pyran ring in the three compounds. The torsion angle between aromatic ring and pyran ring is about 89.452°, 84.160° and 89.801° in compounds **5**, **8** and **12** respectively.

2.2. Quantum Chemical Calculations {#sec2dot2-molecules-20-17469}
----------------------------------

### 2.2.1. Geometric Parameters of Compounds **1**--**4** {#sec2dot2dot1-molecules-20-17469}

The fully optimized molecular structures of biscoumarins **1**--**4** with atomic numbering calculated at B3LYP level of theory are shown in [Figure 3](#molecules-20-17469-f003){ref-type="fig"}. For compound **4**, experimental geometric parameters and selected calculated geometric parameters under three different basis sets (6-31G\*, 6-31+G\*\*, and 6-311G\*) are presented in [Table 1](#molecules-20-17469-t001){ref-type="table"}.

![Schematic presentation of compounds **1**--**4**.](molecules-20-17469-g003){#molecules-20-17469-f003}

Under three different basis sets, the calculated results are very close with the average discrepancy of the selected bond lengths and bond angles between theoretical and experimental data is less than ± 0.02 Å and ± 2° respectively. B3LYP/6-31G\* exhibited sufficient agreement with experimental data and lower computational cost, so further theoretical study was performed at this level.

molecules-20-17469-t001_Table 1

###### 

Experimental and calculated parameters of the selected bond lengths and bond angles of 3,3′-(3-fluoro-4-chlorobenzylidene)-bis-(4-hydroxycoumarin) (**4**).

                                       X-ray    6-31G\*   6-31+G\*\*   6-311G\*
  ------------------------------------ -------- --------- ------------ ----------
  *R*(C~1~---O~1~)                     1.224    1.234     1.236        1.226
  *R*(C~1~---O~2~)                     1.35     1.372     1.37         1.371
  *R*(C~19~---O~4~)                    1.221    1.23      1.233        1.223
  *R*(C~19~---O~5~)                    1.362    1.375     1.372        1.374
  *R*(C~2~---C~10~)                    1.508    1.526     1.526        1.526
  *R*(C~10~---C~11~)                   1.516    1.525     1.524        1.524
  *R*(C~10~---C~20~)                   1.536    1.539     1.539        1.537
  *A*(C~1~---O~2~---C~9~)              121.11   121.67    121.7        121.7
  *A*(O~1~---C~1~---O~2~)              116.05   115.7     115.9        115.95
  *A*(C~18~---O~5~---C~19~)            121.34   121.9     121.89       121.92
  *A*(O~4~---C~19~---O~5~)             114.64   115.67    115.85       115.96
  *A*(C~2~---C~10~---C~20~)            114.84   115.8     115.94       115.88
  *A*(C~2~---C~10~---C~11~)            113.67   112.59    112.77       112.68
  *A*(C~11~---C~10~---C~20~)           113.79   114.51    114.61       114.57
  *D*(C~1~---C~2~---C~10~---C~20~)     137.5    133.73    133.05       133.63
  *D*(C~1~---C~2~---C~10~---C~11~)     89.01    91.83     92.01        91.65
  *D*(C~12~---C~11~---C~10~---C~20~)   129.87   131.31    130.59       130.23
  *D*(C~12~---C~11~---C~10~---C~2~)    96.14    93.64     93.85        94.44

### 2.2.2. Estimation of the Single and Total HB Energies in Compounds **1**--**4** {#sec2dot2dot2-molecules-20-17469}

We estimate single and total HB energies of compound 4 as an example. The global minimum structure is stabilized by two HBs (4ab); two higher energy structures is stabilized by one HB (4a and 4b) respectively.

From [Table 2](#molecules-20-17469-t002){ref-type="table"} we can see that, the O~6~---H~6~···O~1~ HB energy was estimated to be −51.402039 kJ/mol by the equation $\text{E}\left( {\text{O}_{6}—\text{H}_{6}\ldots\text{O}_{1}} \right) = \text{E}_{4\text{ab}}^{\text{coor}} - \text{E}_{4\text{a}}^{\text{coor}}$, is from the energy difference between 4ab and 4a (4a is a global minimum structure with O~3~---H~3~···O~4~ HB). Similarly, the O~3~---H~3~···O~4~ HB energy was calculated to be −65.4353365 kJ/mol by the equation $\text{E}\left( {\text{O}_{3}—\text{H}_{3}\ldots\text{O}_{4}} \right) = \text{E}_{4\text{ab}}^{\text{coor}} - \text{E}_{4\text{b}}^{\text{coor}}$, is from the energy difference between 4ab and 4b (4b was obtained from the global minimum structure 4ab, but H~3~ was rotated around the C~3~---O~3~ bond until O~3~---H~3~···O~4~ HB rupture occurred \[[@B12-molecules-20-17469],[@B13-molecules-20-17469]\]).
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###### 

Total electronic energies (in hartree) and hydrogen bond (HB) energies (in kJ/mol) of hydrogen bonded conformers of compounds **1**--**4** calculated at B3LYP/6-31G\* level of theory.

  System   Total Electronic Energies ^a^   E(O~6~---H~6~···O~1~)   E(O~3~---H~3~···O~4~)   E(Total HB)
  -------- ------------------------------- ----------------------- ----------------------- --------------
  1ab      −1452.593097                                                                    −119.118935
  1a       −1491.908094                    −52.4391115                                     
  1b       −1491.888121                                            −67.1051545             
  2ab      −1603.031177                                                                    −122.1776425
  2a       −1603.011081                    −52.762048                                      
  2b       −1603.004738                                            −69.4155945             
  3ab      −4083.681309                                                                    −116.1757495
  3a       −4083.66182                     −51.1683695                                     
  3b       −4083.656549                                            −65.00738               
  4ab      −1972.171758                                                                    −116.8373755
  4a       −1972.15218                     −51.402039                                      
  4b       −1972.146835                                            −65.4353365             

^a^ ZP corrected.

The total HB energy in compound **4**, calculated by the equation $\text{E}\left( {\text{O}_{3}—\text{H}_{3}\ldots\text{O}_{4}} \right) + \text{E}\left( {\text{O}_{6}—\text{H}_{6}\ldots\text{O}_{1}} \right)$, was estimated to be −116.8373755 kJ/mol. For compounds **1**--**3**, their total HB energies are −119.118935, −122.1776425 and −116.1757495 kJ·mol^−1^, respectively.

2.3. Minimal Inhibitory Concentration (MIC) Assay {#sec2dot3-molecules-20-17469}
-------------------------------------------------

For compounds **1**--**13**, one drug-sensitive *S. aureus* (*S. aureus* ATCC 29213) strain and three MRSA strains (MRSA XJ 75302, Mu50, USA 300 LAC), one drug-sensitive *S. epidermidis* strain (*S. epidermidis* ATCC 14990) and one methicillin-resistant *S. epidermidis* strain (MRSE XJ 75284) were used in the systematic analysis of their antibacterial activities *in vitro*. From [Table 3](#molecules-20-17469-t003){ref-type="table"} we can see that in all the synthesized compounds, biscoumarin derivatives **3** and **4** exerted more potent anti-bacterial activity against all tested strains expect for *E. Coli* with the MIC values of 8--16 μg/mL. Compared with compounds **1**--**13**, the MIC values of levofloxacin, ceftazidime, ceftriaxone, gentamicin, piperacillin and vancomycin against *S. aureus* (ATCC 29213) strain were lower (less than 8 μg/mL) but were higher against other strains at varying degrees.

molecules-20-17469-t003_Table 3

###### 

Minimum inhibitory concentrations (MIC) of compounds **1**--**13** and antibiotics in Mueller-Hinton broth culture.

  Drugs             MIC (μg/mL)                                                                          
  ----------------- --------------- ------------- ------------- ------------ ------------- ------------- -------------
  Compound **1**    \>256           \>256         \>256         \>256        \>256         \>256         \>256
  Compound **2**    \>256           \>256         \>256         \>256        \>256         \>256         \>256
  Compound **3**    16              16            8             8            8             8             \>256
  Compound **4**    8               8             8             8            8             8             \>256
  Compound **5**    \>256           \>256         \>256         \>256        \>256         \>256         \>256
  Compound **6**    \>256           \>256         \>256         \>256        \>256         \>256         \>256
  Compound **7**    \>256           \>256         \>256         \>256        \>256         \>256         \>256
  Compound **8**    \>256           \>256         \>256         \>256        \>256         \>256         \>256
  Compound **9**    \>256           \>256         \>256         \>256        \>256         \>256         \>256
  Compound **10**   \>256           \>256         \>256         \>256        \>256         \>256         \>256
  Compound **11**   \>256           \>256         \>256         \>256        \>256         \>256         \>256
  Compound **12**   \>256           \>256         \>256         \>256        \>256         \>256         \>256
  Compound **13**   \>256           \>256         \>256         \>256        \>256         \>256         \>256
  Levofloxacin      \<0.125 (*S*)   4 (*R*)       4 (*R*)       8 (*R*)      0.125 (*S*)   0.125 (*S*)   0.25 (*S*)
  Ceftazidime       8 (*S*)         \>256 (*R*)   256 (*R*)     64 (*R*)     1 (*S*)       256 (*R*)     0.25 (*S*)
  Ceftriaxone       2 (*S*)         \>256 (*R*)   256 (*R*)     32 (*R*)     1 (*S*)       256 (*S*)     0.25 (*S*)
  Gentamicin        0.12 (*S*)      64 (*R*)      32 (*R*)      0.25 (*S*)   0.25 (*S*)    32 (*R*)      2 (*S*)
  Piperacillin      2 (*S*)         \>128 (*R*)   \>128 (*R*)   8 (*R*)      2 (*S*)       \>128 (*R*)   2 (*S*)
  Vancomycin        0.25 (*S*)      8 (*I*)       8 (*I*)       0.5 (*S*)    0.25 (*S*)    0.5 (*S*)     \>256 (*R*)

*S* means drug susceptibility, *R* means drug resistance, *I* means intermediate resistance.

2.4. In Vitro Toxicity Measurement {#sec2dot4-molecules-20-17469}
----------------------------------

To further explore the safety of the possible development, we investigated the cytotoxicity of compounds **3** and **4** to human umbilical vein endothelial cells (HUVECs) and human embryonic cardiomyocyte cell line CCC-HHM-2 (HHHM-2) in vitro. As shown in [Figure 4](#molecules-20-17469-f004){ref-type="fig"}, there was no obvious inhibitory effect of compounds 3 and 4 on cell viability at a concentration between 6.25 to 200 μg·mL^−1^, and the IC~50~ of compound **3** to the HUVECs and HHHM-2 was 1268.25 μg·mL^−1^ and 1036.56 μg·mL^−1^, the corresponding value of compound **4** was 1145.36 μg·mL^−1^ and 916.14 μg·mL^−1^. These results implied that compounds **3** and **4** had much less toxicity to mammalian cells, and had a relatively wide safety range for potential antimicrobial applications.

![Cytotoxicity measurement of compounds **3** and **4** on the human umbilical vein endothelial cells (HUVECs) and human embryonic cardiomyocyte cell line CCC-HHM-2 (HHHM-2) *in vitro*.](molecules-20-17469-g004){#molecules-20-17469-f004}

2.5. Discussion {#sec2dot5-molecules-20-17469}
---------------

Methicillin-resistant *S. aureus* (MRSA) and is the cause of major outbreaks and epidemics in hospitalized patients because of the emergence, spread, and rapid evolution of resistance genes developing among pathogens. As such, the mortality and morbidity rates of patients affected by MRSA are high. However, the emergence of vancomycin-resistant *S. aureus* and treatment failure of MRSA infections urgently requires developing new antimicrobials.

In this work, among two kinds of compounds, novel biscoumarin derivatives **3** and **4** were demonstrated to be capable of remarkably inhibiting the growth of all tested strains expect for *E. coli* with the MIC value of 8--16 μg/mL. However, compared with compounds **3** and **4**, other biscoumarins **1** and **2** and dihydropyran derivatives **5**--**13** almost have no antibacterial activities. In addition, the results of *in vitro* toxicity study of compounds **3** and **4** on HUVECs and HHHM-2 revealed that the two compounds had a relatively wide safety range for potential antimicrobial applications with much less toxicity to mammalian cells.

X-ray structural analysis also showed that biscoumarins **1**--**4** were stabilized by two asymmetrical intramolecular O---H···O HBs, which were considered as important factors in assisting the molecule to attain the correct configuration for biological activity \[[@B14-molecules-20-17469]\]. The total HB stabilization energies in compounds **1**--**4** were estimated to be −119.118935, −122.1776425, −116.1757495 and −116.8373755 kJ·mol^−1^, respectively. These values suggest that the most potent antibacterial activity in compounds **3** and **4** was consistent with their weakest HB strengths.

3. Experimental Section {#sec3-molecules-20-17469}
=======================

3.1. Apparatus and Materials {#sec3dot1-molecules-20-17469}
----------------------------

IR spectra (400--4000 cm^−1^) were obtained using a Brucker Equinox-55 spectrophotometer (Fremont, CA, USA). ^1^H-NMR spectra were obtained using a Varian Inova-400 spectrometer (at 400 MHz) (Palo Alto, CA, USA). Mass spectra were obtained using a micrOTOF-Q II mass spectrometer (Bruker). The melting points were taken on a XT-4 micro melting apparatus (Taike Company, Beijing, China), and the thermometer was uncorrected.

All antibiotics used were purchased from the National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China). All other chemicals and solvents were of analytical grade.

MRSA (XJ 75302) and MRSE (XJ 75284) were isolated from cultures of sputum samples from patients in Xijing Hospital (Xi'an, China). *S. aureus* (ATCC 29213), *S. epidermidis* (ATCC 14990) and *E. coli* (ATCC 25922) strains were purchased from the Chinese National Center for Surveillance of Antimicrobial Resistance. Mu50 (ATCC 700699) and USA 300 (LAC) were purchased from MicroBiologics (St. Cloud, MN, USA).

3.2. Synthesis and Characterization of Compounds **1**--**13** {#sec3dot2-molecules-20-17469}
--------------------------------------------------------------

Biscoumarins **1**--**4** were synthesized according to the methods of a previous report \[[@B15-molecules-20-17469]\]. A mixture of 3,4-dimethylbenzaldehyde (3-hydroxy-4-methoxybenzaldehyde, 3-bromo-4-fluorobenzaldehyde, 3-fluoro-4-chlorobenzaldehyde) (10 mmol) and 4-hydroxycoumarin (20 mmol) was dissolved in 100 mL of EtOH. A few drops of piperidine were added, and the mixture was stirred for 3 h at room temperature. After reaction completion as determined by TLC, water was added until precipitation occurred. The solid was filtered off and then recrystallized from ethanol to give compounds **1**--**4**.

*3,3′-(3,4-Dimethylbenzylidene)-bis-(4-hydroxycoumarin)* (**1**): m.p. 227--228 °C. IR (KBr pellet cm^−1^): 2922, 1671, 1601, 1561, 1342, 1303, 1094, 766 cm^−1^. ^1^H-NMR (CDCl~3~, δ, ppm): 11.507 (s, 1H), 11.268 (s, 1H), 8.015--8.065 (q, 2H), 7.606--7.647 (t, 2H), 7.404--7.425 (d, 4H), 7.067--7.088 (d, 1H), 6.950 (s, 2H), 6.049 (s, 1H), 2.204 (s, 3H), 2.241 (s, 3H). HRMS (ESI^+^): *m*/*z*: calcd for C~27~H~20~O~6~: 463.1152 \[M + Na\]^+^; found: 463.1135.

*3,3′-(3-Hydroxy-4-methoxybenzylidene)-bis-(4-hydroxycoumarin)* (**2**): m.p. 246--247 °C. IR (KBr pellet cm^−1^): 3530, 2608, 1667, 1615, 1567, 1512, 1453, 1350, 1269, 1215, 1095, 1028, 763 cm^−1^. ^1^H-NMR (CDCl~3~, δ, ppm): 11.612 (s, 1H), 11.277 (s, 1H), 8.034--8.070 (d, 2H), 7.623--7.666 (m, 2H), 7.414--7.435 (d, 4H), 6.799--6.819 (t, 2H), 6.708--6.729 (t, 1H), 6.047 (s, 1H), 5.612 (s, 1H), 3.895 (s, 3H). HRMS (ESI^+^): *m*/*z*: calcd for C~26~H~18~O~8~: 481.0894 \[M + Na\]^+^; found: 481.7855.

*3,3′-(3-Bromo-4-fluorobenzylidene)-bis-(4-hydroxycoumarin)* (**3**): m.p. 215--216 °C. IR (KBr pellet cm^−1^): 1666, 1617, 1567, 1495, 1348, 1097, 1047, 763 cm^−1^. ^1^H-NMR (DMSO-*d*~6~, δ, ppm): 7.885--7.901 (d, 3H), 7.763 (s, 2H), 7.562--7.601 (t, 2H), 7.279--7.357 (m, 4H), 6.403 (s, 1H). HRMS (ESI^+^): *m*/*z*: calcd for C~25~H~14~BrFO~6~: 530.9850 \[M + Na\]^+^; found: 530.9865.

*3,3′-(3-Fluoro-4-chlorobenzylidene)-bis-(4-hydroxycoumarin)* (**4**): m.p. 259--260 °C. IR (KBr pellet cm^−1^): 3448, 3083, 1790, 1670, 1611, 1561, 1489, 1413, 1259, 1172, 1064, 863, 767 cm^−1^. ^1^H-NMR (CDCl~3~, δ, ppm): 11.626 (s, 1H), 11.344 (s, 1H), 8.020--8.107 (m, 2H), 7.656--7.699 (m, 2H), 7.340--7.458 (m, 5H), 6.972--7.055 (m, 2H), 6.054 (s, 1H). HRMS (ESI^+^): *m*/*z*: calcd for C~25~H~14~ClFO~6~: 487.0355 \[M + Na\]^+^; found: 487.0433.

Dihydropyran derivatives (**5**--**13**) were also synthesized according to a reported procedure \[[@B16-molecules-20-17469]\]. A mixture of 4-hydroxycoumarin (1-naphthalenol, 1,1-dimethyl-3,5-cyclohexanedione) (10 mmol), aromatic aldehydes (10 mmol), malononitrile (10 mmol) and 4-(dimethylamino)pyridine (DMAP) (1 mmol) in ethanol (100 mL) was refluxed for 2--3 h and then cooled to room temperature. The solid was filtered off and then recrystallized from ethanol to give compounds **5**--**13**.

*2-Amino-4-(4-hydroxyphenyl)-3-cyano-5-oxo-4H,5H-pyrano\[3,2c\]chromene* (**5**): m.p. 269--270 °C. IR (KBr pellet cm^−1^): 3511, 3279, 2191, 1694, 1670, 1606, 1382, 1262, 1165, 1069, 757 cm^−1^. ^1^H-NMR (DMSO-*d*~6~, δ, ppm): 9.387 (s, 1H), 7.879--7.902 (q, 1H), 7.684--7.727 (m, 1H), 7.447--7.507 (q, 2H), 7.356 (s, 2H), 7.034--7.055 (d, 2H), 6.679--6.700 (d, 2H), 4.331 (s, 1H). HRMS (ESI^+^): *m*/*z*: calcd for C~19~H~12~N~2~O~4~: 355.0689 \[M + Na\]^+^; found: 355.0680.

*2-Amino-4-(4-chlorophenyl)-3-cyano-5-oxo-4H,5H-pyrano\[3,2c\]chromene* (**6**): m.p. 254--255 °C. IR (KBr pellet cm^−1^): 3386, 3312, 3190, 2193, 1714, 1675, 1610, 1490, 1377, 1060, 759 cm^−1^. ^1^H-NMR (DMSO-*d*~6~, δ, ppm): 7.889--7.913 (q, 1H), 7.703--7.746 (m, 1H), 7.461--7.521 (m, 4H), 7.359--7.386 (m, 2H), 7.301--7.328 (m, 2H), 4.493 (s, 1H). HRMS (ESI^+^): *m*/*z*: calcd for C~19~H~11~ClN~2~O~3~: 373.0350 \[M + Na\]^+^; found: 373.2438.

*2-Amino-4-(4-nitrophenyl)-3-cyano-5-oxo-4H,5H-pyrano\[3,2c\]chromene* (**7**): m.p. 259--260 °C. IR (KBr pellet cm^−1^): 3688, 2191, 1718, 1662, 1509, 1341, 1253, 1053, 957, 901, 765 cm^−1^. ^1^H-NMR (DMSO-*d*~6~, δ, ppm): 8.175--8.196 (d, 2H), 7.910--7.933 (q, 1H), 7.723--7.766 (m, 1H), 7.475--7.611 (m, 6H), 4.682 (s, 1H). HRMS (ESI^+^): *m*/*z*: calcd for C~19~H~11~N~3~O~5~: 384.0591 \[M + Na\]^+^; found: 384.0533.

*2-Amino-4-(3-phenoxyphenyl)-4H-benzo\[h\]chromene-3-carbonitrile* (**8**): m.p. 173--174 °C. IR (KBr pellet cm^−1^): 3337, 1627, 1573, 1488, 1445, 1378, 1240, 1189, 1105, 1025, 892, 758 cm^−1^. ^1^H-NMR (DMSO-*d*~6~, δ, ppm): 8.221--8.241 (d, 1H), 7.899--7.919 (d, 1H), 7.567--7.661 (m, 3H), 7.301--7.389 (m, 3H), 7.112--7.206 (m, 4H), 6.979--7.008 (t, 4H), 6.796--6.822 (q, 1H), 4.938 (s, 1H). HRMS (ESI^+^): *m*/*z*: calcd for C~26~H~18~N~2~O~2~: 413.1260 \[M + Na\]^+^; found: 413.1255.

*2-Amino-4-(4-methanesulfonylphenyl)-4H-benzo\[h\]chromene-3-carbonitrile* (**9**): m.p. 244--245 °C. IR (KBr pellet cm^−1^): 3001, 1629, 1573, 1487, 1412, 1304, 1234, 1190, 1150, 1103, 1016, 764 cm^−1^. ^1^H-NMR (DMSO-*d*~6~, δ, ppm): 8.246--8.267 (d, 1H), 7.887--7.925 (t, 3H), 7.602--7.683 (m, 3H), 7.523--7.544 (d, 2H), 7.039 (s, 2H), 7.116--7.138 (d, 1H), 5.106 (s, 1H), 3.203 (s, 3H). HRMS (ESI^+^): *m*/*z*: calcd for C~21~H~16~N~2~O~3~S: 399.0774 \[M + Na\]^+^; found: 399.0723.

*2-Amino-4-(4-nitrophenyl)-4H-benzo\[h\]chromene-3-carbonitrile* (**10**): m.p. 241--242 °C. IR (KBr pellet cm^−1^): 3477, 1651, 1512, 1404, 1350, 1185, 1101, 1022, 801, 770 cm^−1^. ^1^H-NMR (DMSO-*d*~6~, δ, ppm): 8.198--8.272 (q, 3H), 7.905--7.926 (d, 1H), 7.538--7.685 (m, 5H), 7.343 (s, 2H), 7.106--7.128 (d, 1H), 5.164 (s, 1H). HRMS (ESI^+^): *m*/*z*: calcd for C~20~H~13~N~3~O~3~: 366.0849 \[M + Na\]^+^; found: 366.0831.

*2-Amino-4-(4-methoxyphenyl)-3-cyano-7,7-dimethyl-5-oxo-4H-5,6,7,8-tetrahydrobenzo\[b\]pyran* (**11**): m.p. 209--210 °C. IR (KBr pellet cm^−1^): 3320, 3187, 2198, 1685, 1649, 1606, 1582, 1509, 1462, 1411, 1370, 1247, 1033, 842 cm^−1^. ^1^H-NMR (DMSO-*d~6~*, δ, ppm): 7.045--7.067 (d, 2H), 6.954 (s, 2H), 6.834--6.855 (d, 2H), 4.124 (s, 1H), 3.718 (s, 3H), 2.452--2.508 (q, 2H), 2.229--2.269 (d, 1H), 2.075--2.115 (d, 1H), 1.039 (s, 3H), 0.952 (s, 3H). HRMS (ESI^+^): *m*/*z*: calcd for C~19~H~20~N~2~O~3~: 347.1366 \[M + Na\]^+^; found: 347.1324.

*2-Amino-3-cyano-4-phenyl-7,7-dimethyl-5-oxo-4H-5,6,7,8-tetrahydrobenzo\[b\]pyran* (**12**): m.p. 219--220 °C. IR (KBr pellet cm^−1^): 3213, 2961, 2199, 1689, 1603, 1492, 1454, 1413, 1372, 1217, 1035, 838 cm^−1^. ^1^H-NMR (DMSO-*d*~6~, δ, ppm): 7.273--7.311 (t, 2H), 7.136--7.205 (m, 3H), 6.999 (s, 2H), 4.176 (s, 1H), 2.503--2.526 (m, 1H), 2.240--2.281 (d, 1H), 2.130 (s, 1H), 2.092 (s, 1H), 1.046 (s, 3H), 0.963 (s, 3H). HRMS (ESI^+^): *m*/*z*: calcd for C~18~H~18~N~2~O~2~: 317.1260 \[M + Na\]^+^; found: 317.1344.

*2-Amino-4-(2,4-dinitrophenyl)-3-cyano-7,7-dimethyl-5-oxo-4H-5,6,7,8-tetrahydrobenzo\[b\]pyran* (**13**): m.p. 217--218 °C. IR (KBr pellet cm^−1^): 3422, 2202, 1682, 1664, 1602, 1537, 1361, 1216, 1044 cm^−1^. ^1^H-NMR (DMSO-*d*~6~, δ, ppm): 8.619--8.625 (d, 1H), 8.434--8.462 (m, 1H), 7.707--7.729 (d, 1H), 7.374 (s, 2H), 4.989 (s, 1H), 2.202--2.243 (d, 1H), 2.091 (s, 2H), 2.009--2.050 (d, 1H), 1.027 (s, 3H), 0.898 (s, 3H). HRMS (ESI^+^): *m*/*z*: calcd for C~18~H~16~N~4~O~6~: 407.0962 \[M + Na^+^\]; found: 407.0945.

3.3. X-ray Crystallography {#sec3dot3-molecules-20-17469}
--------------------------

For X-ray diffraction experiments, single crystals of compounds **4**, **5**, **8** and **12** were both grown from methanol. The X-ray diffraction data were collected on a Bruker SMART APEX II CCD diffractometer equipped with a graphite monochromated Mo Kα radiation (λ = 0.71073 Å) by using the *ω*-2*θ* scan technique at room temperature. The structure was solved by direct methods using SHELXL-97 \[[@B17-molecules-20-17469]\] and refined using the full-matrix least squares method on *F*^2^ with anisotropic thermal parameters for all non-hydrogen atoms by using SHELXL-97. Hydrogen atoms were generated geometrically. The crystal data and details concerning data collection and structure refinement are given in [Table 4](#molecules-20-17469-t004){ref-type="table"}. Molecular illustrations were prepared using the XP package. Parameters in CIF format are available as Electronic Supplementary Publication from Cambridge Crystallographic Data Centre.

molecules-20-17469-t004_Table 4

###### 

Crystal data, data collection and structure refinement of compounds **4**, **5**, **8** and **12**.

                                  Compound 4          Compound 5           Compound 8           Compound 12
  ------------------------------- ------------------- -------------------- -------------------- --------------------
  Formula                         C~25~H~14~ClFO~6~   C~19~H~12~N~2~O~4~   C~26~H~18~N~2~O~2~   C~18~H~18~N~2~O~2~
  *M*r                            464.0463            332.0797             390.1368             294.1368
  Crystal system                  Monoclinic          Monoclinic           Monoclinic           Monoclinic
  Space group                     P2~1~/c             P2~1~/c              P2~1~/c              P2~1~/c
  *a*/Å                           10.1874(7)          8.8632(6)            11.908(3)            11.2938(5)
  *b*/Å                           10.1667(6)          13.1743(8)           15.4731(17)          9.4591(5)
  *c*/Å                           20.0790(12)         13.0565(6)           11.9343(18)          14.9132(7)
  α/°                             90                  90                   90                   90
  β/°                             96.571(7)           94.484(6)            116.15(2)            99.304(4)
  γ/°                             90                  90                   90                   90
  *V*/Å^3^                        2066.0(2)           1519.89(15)          1973.9(6)            1572.21(13)
  *Z*                             4                   4                    4                    4
  *D*~calc~/g·cm^−3^              1.491               1.452                1.314                1.244
  μ(Mo Kα)/mm^−1^                 0.236               0.104                0.084                0.082
  θ range/°                       2.70 to 25.00       2.78 to 25.00        2.63 to 25.00        2.56 to 25.00
  Reflections collected           7346                5980                 4969                 6337
  No. unique data \[*R*(int)\]    3621 \[0.0256\]     2670 \[0.0263\]      3099 \[0.0186\]      2775 \[0.0280\]
  No. data with *I* ≥ 2*σ*(*I*)   2293                1991                 2029                 2109
  *R*~1~                          0.0501              0.0453               0.0542               0.0465
  *ωR*~2~(all data)               0.1704              0.1559               0.1561               0.1627
  CCDC                            1032644             1032645              1032646              1032647

3.4. Quantum Chemical Calculations {#sec3dot4-molecules-20-17469}
----------------------------------

All calculations were carried out using the Gaussian 09 package \[[@B18-molecules-20-17469]\]. Density functional theory (DFT) \[[@B19-molecules-20-17469]\], Becke's three-parameter hybrid function (B3LYP) \[[@B20-molecules-20-17469]\], and LYP correlation function \[[@B21-molecules-20-17469],[@B22-molecules-20-17469]\] were used to fully optimize all the geometries on the energy surface without constraints. To obtain precise results that are in conjunction with experimental results, three basis sets, namely 6-31G\*, 6-31+G\*\*, and 6-311G\*, were tested. Frequency calculations at the B3LYP (with basis sets 6-31G\*) level of theory were carried out to confirm stationary points as minima and to obtain the zero-point energies and the thermal correlation data at 1 atm and 298 K.

3.5. Minimal Inhibitory Concentration (MIC) Assay {#sec3dot5-molecules-20-17469}
-------------------------------------------------

Based on the CLSI broth microdilution method \[[@B23-molecules-20-17469]\], the determination of minimum inhibitory concentrations (MICs) via microdilution assay was performed in sterilized 96-well polypropylene microtiter plates (Sigma-Aldrich, St. Louis, MO, USA) in a final volume of 200 μL. Bacteria were grown overnight in nutrient broth. Mueller-Hinton (MH) broth (100 μL) containing bacteria (5 × 10^5^ CFU/mL) was added to 100 μL of the culture medium containing the test compound (0.12 μg/mL to 256 μg/mL in serial twofold dilutions). The plates were incubated at 37 °C for 20 h in an incubator. About 50 µL of 0.2% triphenyl tetrazolium chloride (TTC), a colorimetric indicator, was added to each well of microtiter plates and incubated at 35 °C for 1.5 h. The TTC-based MIC was determined as the lowest concentration of oxacillin that showed no red color change indicating complete growth inhibition. The data were from three repeated experiments.

3.6. Cytotoxicity Assay {#sec3dot6-molecules-20-17469}
-----------------------

The cytotoxicity of compounds **3** and **4** to the human umbilical vein endothelial cells (HUVECs) and the human embryonic cardiomyocyte cell line CCC-HHM-2 (HHHM-2) was determined by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) staining. Briefly, cells (5 × 10^3^ cells per well) were seeded in a 96-well plate with 100 μL DMEM medium with 20% fetal bovine serum (FBS) in each well for 12 h and then treated with or without compounds at various concentrations (12.5--800 μg·mL^−1^) for 24 h. After treatment, MTT solution (final concentration, 0.5%) was added and cells were incubated for another 4 h at 37 °C. 150 μL DMSO was added to each well after removal of the supernatant and the absorbance at 490 nm was measured with a microplate reader.

4. Conclusions {#sec4-molecules-20-17469}
==============

With the emergence of methicillin-resistant, vancomycin intermediate-resistant, or multi-drug-resistant *S. aureus*, more appropriate antibiotics need to be developed. Our results showed that biscoumarin derivatives **3** and **4** have better anti-bacterial efficiency with minimum MIC value of 8--16 μg/mL in all synthesized compounds, which is may be that there are two intramolecular O---H···O HBs in their structures and two strong electron-withdrawing atoms (Br and F; F and Cl) further weakens the total HB energy.
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